Business Context and Reporting Period
Company: AYTU BIOSCIENCE, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: August 11, 2017 (Event Date)
Reporting Period: The filing covers a private placement offering closed on August 15, 2017, and the termination of a prior purchase agreement effective August 16, 2017.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than standard operating financial results. Key metrics include:
- Gross Proceeds: Approximately $11.8 million.
- Securities Issued:
- 63,933,298 shares of Common Stock.
- 2,250 shares of Series A Convertible Preferred Stock.
- Warrants to purchase up to 118,399,947 shares of Common Stock.
- Pricing:
- Class A Units (Common Stock + Warrants): $0.15 per unit.
- Class B Units (Series A Preferred + Warrants): $1,000 per unit (for investors exceeding 9.99% beneficial ownership).
- Warrant Exercise Price: $0.18 per share (subject to reduction to $0.15 if a reverse split is not effected by August 26, 2017).
- Use of Proceeds: Sales and marketing for Natesto® commercialization, working capital, and general corporate purposes.
Material Changes and Agreements
Entry into Material Definitive Agreement (Item 1.01): The company entered into a Securities Purchase Agreement and a Registration Rights Agreement. Key terms include:
- Registration Rights: The company must file a Form S-1 registration statement by September 5, 2017. Failure to declare it effective by October 5, 2017, triggers a penalty of 2% of the purchase price per month.
- Participation Rights: Investors have the right to participate in up to 35% of any subsequent financing for 24 months following the Effective Date.
- Issuance Restrictions: The company is restricted from issuing new equity or equivalents for 270 days after the Effective Date or 365 days from August 15, 2017, unless approved by 51% of the offering investors. This restriction terminates if the stock price exceeds $1.00 for five consecutive trading days.
- Variable Rate Transactions: Prohibited until all warrants are no longer held by investors.
Termination of Material Definitive Agreement (Item 1.02): The company terminated a Purchase Agreement with Lincoln Park Capital Fund, LLC, dated July 27, 2016. Under the prior agreement, the company had sold 386,190 shares for $740,000 in gross proceeds.
Outlook, Risks, and Contingencies
- Regulatory Risk: The company faces a strict deadline to file and have declared effective a registration statement to avoid monthly penalty payments to investors.
- Dilution Risk: The offering included a significant number of warrants (118.4 million shares) with a low exercise price, creating substantial potential dilution. Warrants are exercisable upon a one-for-twenty reverse split or 45 days post-closing.
- Liquidity Constraints: Proceeds are designated for commercialization and working capital, indicating a need for liquidity to support operations.
- Market Conditions: The warrant exercise price is subject to downward adjustment if the company issues securities at a price lower than the current exercise price (anti-dilution provision).
Investor Verification Checklist
- Verify the status of the Form S-1 registration statement required by September 5, 2017, to assess potential penalty liabilities.
- Confirm whether the one-for-twenty reverse stock split was effected by August 26, 2017, to determine the final warrant exercise price ($0.18 vs. $0.15).
- Review the company's cash burn rate and working capital runway given the stated use of proceeds for commercialization.
- Monitor the stock price relative to the $1.00 threshold, which would lift the 270/365-day issuance restriction.
- Assess the impact of the 118.4 million warrant shares on future earnings per share (EPS) and ownership dilution.